CN117120100A - 前列腺癌的诊断方法 - Google Patents

前列腺癌的诊断方法 Download PDF

Info

Publication number
CN117120100A
CN117120100A CN202280026305.2A CN202280026305A CN117120100A CN 117120100 A CN117120100 A CN 117120100A CN 202280026305 A CN202280026305 A CN 202280026305A CN 117120100 A CN117120100 A CN 117120100A
Authority
CN
China
Prior art keywords
radioligand
psma
imaging agent
pet
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280026305.2A
Other languages
English (en)
Chinese (zh)
Inventor
A·卡塔福
E·帕雷拉皮耶拉
B·赫
E·卡帕梅根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Advanced Accelerator Applications SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Advanced Accelerator Applications SA filed Critical Novartis AG
Publication of CN117120100A publication Critical patent/CN117120100A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202280026305.2A 2021-04-02 2022-04-01 前列腺癌的诊断方法 Pending CN117120100A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305432 2021-04-02
EP21305432.3 2021-04-02
PCT/EP2022/058754 WO2022207906A1 (en) 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer

Publications (1)

Publication Number Publication Date
CN117120100A true CN117120100A (zh) 2023-11-24

Family

ID=75588163

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280026305.2A Pending CN117120100A (zh) 2021-04-02 2022-04-01 前列腺癌的诊断方法

Country Status (9)

Country Link
US (1) US20240181092A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313175A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514293A (cg-RX-API-DMAC7.html)
KR (1) KR20230165761A (cg-RX-API-DMAC7.html)
CN (1) CN117120100A (cg-RX-API-DMAC7.html)
CA (1) CA3215723A1 (cg-RX-API-DMAC7.html)
IL (1) IL307381A (cg-RX-API-DMAC7.html)
TW (1) TW202304531A (cg-RX-API-DMAC7.html)
WO (1) WO2022207906A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
CN120897762A (zh) * 2023-04-12 2025-11-04 康奈尔大学 用于治疗癌症的放射治疗缀合物
WO2026027442A1 (en) 2024-08-01 2026-02-05 Novartis Ag Synthesis of a precursor of radiopharmaceutical products

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020528461A (ja) * 2017-07-28 2020-09-24 テクニシェ ユニバーシタット ミュンヘン デュアルモードの放射性トレーサーおよび療法剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173630A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Formulation of radiopharmaceuticals containing multiple acidic groups
WO2013173583A1 (en) 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
SMT202300035T1 (it) * 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020528461A (ja) * 2017-07-28 2020-09-24 テクニシェ ユニバーシタット ミュンヘン デュアルモードの放射性トレーサーおよび療法剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AFSHAR-OROMIEH 等: "The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer", EUR J NUCL MED MOL IMAGING, 31 December 2015 (2015-12-31), pages 197 - 209 *
SPENCER C. BEHR 等: "Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer", JOURNAL OF NUCLEAR MEDICINE, vol. 60, no. 7, 1 July 2019 (2019-07-01), pages 910 - 916 *

Also Published As

Publication number Publication date
TW202304531A (zh) 2023-02-01
JP2024514293A (ja) 2024-04-01
WO2022207906A1 (en) 2022-10-06
IL307381A (en) 2023-11-01
KR20230165761A (ko) 2023-12-05
CA3215723A1 (en) 2022-10-06
EP4313175A1 (en) 2024-02-07
US20240181092A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
Hicks et al. 64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy
Granov et al. Positron emission tomography
Rauscher et al. Intrapatient comparison of 111In-PSMA I&T SPECT/CT and hybrid 68Ga-HBED-CC PSMA PET in patients with early recurrent prostate cancer
McCarthy et al. Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma
JP2024514293A (ja) 前立腺がんの診断方法
Natarajan et al. Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model
La et al. Progress of coordination and utilization of zirconium-89 for positron emission tomography (PET) studies
US20250025584A1 (en) Radiopharmaceutical treatment methods and use
JP2017503763A (ja) Gcc発現細胞を撮像するための化合物及び組成物
Ilem-Ozdemir et al. Nuclear medicine and radiopharmaceuticals for molecular diagnosis
Hodolic et al. Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pancreatic ductal adenocarcinoma: the first in-human use
US20250269073A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
Vernekar et al. Radiopharmaceuticals: a new vista for diagnosis and treatment of thyroid cancer
Velikyan et al. GMP production of [68Ga] Ga-BOT5035 for imaging of liver fibrosis in microdosing phase 0 study
US20250121103A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
Suh et al. Phase I clinical trial of prostate-specific membrane antigen-targeting 68Ga-NGUL PET/CT in healthy volunteers and patients with prostate cancer
KR20260049617A (ko) Cu-64 psma i&t 주사를 사용하여 인간 대상체에서 전립선암을 검출하는 방법
US20250032651A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
O'Brien et al. Managing a high-specific-activity iobenguane therapy clinic: from operations to reimbursement
US20260115337A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
US20240042067A1 (en) [177lu] lutetium-psma i&t composition, kit, method of making, and method of using thereof
Lucignani Non-standard PET radionuclides: time to get ready for new clinical PET strategies
Elison et al. ANZSNM ASM 2021 POSTER PRESENTATIONS
WO2026019453A1 (en) [177lu]lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
HELIA XVII CONGRESS OF THE HEVESY GYÖRGY HUNGARIAN SOCIETY OF NUCLEAR MEDICINE-poster session

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240202

Address after: Basel, SUI

Applicant after: NOVARTIS AG

Country or region after: Switzerland

Address before: French Ruez Farmar Meisong

Applicant before: Advanced accelerator applications Inc.

Country or region before: France

Applicant before: NOVARTIS AG

Country or region before: Switzerland

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination